Shares of Regeneron (NASDAQ:REGN) dropped 4.1% after the company discussed challenges like regulatory approvals and competition at a healthcare forum. Despite highlighting a strong product pipeline, the focus on hurdles worried investors, leading to a 3.7% decrease in stock price to $555.58. The market’s reaction suggests that while significant, this news may not drastically alter perceptions of the business. This decline follows a recent setback involving a court ruling on EYLEA, Regeneron’s eye drug. Currently trading at $556.99, the stock is down 22.1% YTD and 47% from its 52-week high. Interested in thematic investing? Discover a profitable growth stock linked to AI trends here.

Read more at StockStory: Why Regeneron (REGN) Shares Are Falling Today